Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 7/20 | 0.55 |
| ▸ | DGKZ | Q13574 | 7/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25327774 | 1.00 | DGKA (0.55) | DGKADGKZHCRTR2HCRTR1MAPK14 | |
| SCHEMBL21831513 | 0.87 | DGKZ (0.50) | DGKADGKZHCRTR2HCRTR1 | |
| SCHEMBL30554480 | 0.87 | DGKA (0.51) | DGKADGKZHCRTR2HCRTR1MAPK14 | |
| SCHEMBL25329438 | 0.87 | DGKA (0.51) | DGKADGKZHCRTR2HCRTR1MAPK14 | |
| SCHEMBL21831880 | 0.84 | DGKA (0.42) | DGKADGKZHCRTR2MAPK14 | |
| SCHEMBL25329619 | 0.84 | DGKA (0.42) | DGKADGKZHCRTR2MAPK14 | |
| SCHEMBL25330251 | 0.83 | DGKA (0.40) | DGKADGKZHCRTR2HCRTR1 | |
| SCHEMBL21831886 | 0.83 | DGKA (0.40) | DGKADGKZHCRTR2HCRTR1 | |
| SCHEMBL25882894 | 0.82 | DGKA (0.52) | DGKADGKZHCRTR2HCRTR1IDO1 | |
| SCHEMBL25328436 | 0.81 | MAPK14 (0.48) | DGKADGKZMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | DGKA 2/4885DGKZ 1/4885HCRTR2 4502/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DGKA 2/4885DGKZ 1/4885HCRTR2 4502/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DGKA 2/4885DGKZ 1/4885HCRTR2 4502/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DGKA 2/4885DGKZ 1/4885HCRTR2 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.